Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin

Documenti analoghi

• Impact of the timing of metformin administration on the plasma lactate response to intraduodenal glucose infusion in type 2 diabetes
  di: Cong Xie, et al.
  Pubblicazione: (2024)
• Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)
  di: Leili Gao, et al.
  Pubblicazione: (2025)
• Metformin monotherapy versus predominantly older non‐metformin antidiabetic medications for cerebrovascular risk in early type 2 diabetes management
  di: Mingyang Sun, et al.
  Pubblicazione: (2024)
• Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals with type 2 diabetes based on four randomised clinical trials
  di: Weihao Wang, et al.
  Pubblicazione: (2024)
• Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
  di: Yao Wang, et al.
  Pubblicazione: (2024)